Gilead Sciences Gains After EMA Backs Trodelvy-Keytruda Combination

European Endorsement Bolsters Gilead's Oncology Pipeline

Gilead Sciences ($GILD) secured a crucial regulatory milestone on June 18, 2024, as the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for its Trodelvy (sacituzumab govitecan) in combination with Merck’s ($MRK) Keytruda (pembrolizumab). This recommendation is for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥ 10). The endorsement positions the combination therapy to become a new standard of care in a challenging and aggressive cancer subtype.

Following the announcement, Gilead's shares ($GILD) rose by 3.6% to $72.35 in early trading on the Nasdaq, reflecting investor optimism regarding the expanded market access. The move added approximately $3.5 billion to the company's market capitalization, which now stands at $91.8 billion, demonstrating a clear positive sentiment shift towards its oncology segment.

Market Impact

Gilead Sciences ($GILD) closed at $72.35 on June 18, 2024, up 3.6% from its previous close of $69.84. Trading volume spiked to 18.5 million shares, significantly above its 30-day average of 11.2 million shares, indicating strong investor interest. This marks the stock's largest single-day gain since February 2, 2024, when it surged 4.1% following a positive update on its HIV drug pipeline.

The positive movement pushed $GILD above its 50-day moving average of $70.10, signaling a potential shift in short-term momentum. However, the stock remains below its 200-day moving average of $75.20, suggesting that longer-term headwinds or broader market sentiment may still present resistance. The increase contrasts with a modest 0.2% gain for the broader S&P 500 Pharmaceuticals Index ($XPH) on the same day.

The news also indirectly benefited Merck ($MRK), with its shares gaining 0.7% to $125.10. Keytruda's integral role in the combination therapy further solidifies its dominance in the immuno-oncology space, reinforcing its revenue streams. Competitors in the TNBC market, such as Roche ($RHHBY) and AstraZeneca ($AZN), saw minor declines, with $RHHBY down 0.3% to $35.20 and $AZN down 0.1% to $78.90, reflecting potential competitive pressures and shifts in market perception.

What Analysts Are Saying

The CHMP's positive opinion has largely reinforced bullish sentiment among analysts regarding Gilead's oncology strategy. According to RBC Capital Markets analyst Brian Abrahams, this EMA recommendation is a "significant de-risking event" for Trodelvy's expansion into the lucrative first-line TNBC setting. Abrahams reiterated an "Outperform" rating for $GILD with a price target of $90, citing the potential for peak sales of the combination therapy to exceed $3 billion annually in this indication alone within the European market.

Conversely, some analysts remain cautious, suggesting the market had largely anticipated this outcome. BMO Capital Markets' Evan Seigerman noted that while positive, the news limits immediate upside. "The challenge now lies in execution and market penetration against established therapies and pipeline competitors," Seigerman stated, maintaining a "Market Perform" rating and a $75 price target for $GILD. He emphasized that the efficacy data from the EV-103/KEYNOTE-B87 study, which underpinned the CHMP opinion, was already well-known.

Jefferies analyst Michael Yee highlighted the competitive intensity of the TNBC market. He pointed out that Roche's Tecentriq ($RHHBY) already holds a significant market share in the PD-L1 positive TNBC segment. "While the Trodelvy-Keytruda combination shows compelling efficacy, particularly in PD-L1 high expressors, capturing market share will require robust commercial execution and differentiation," Yee commented, setting a "Hold" rating on $GILD with a target of $78. This view underscores the importance of Gilead's commercial strategy in maximizing the therapy's potential.

What to Watch

Investors should closely monitor several key catalysts and risk factors following the CHMP's positive opinion. The most immediate event is the final decision from the European Commission, which is expected within approximately 67 days following the CHMP's recommendation. This decision will grant marketing authorization across all 27 EU member states, formally opening the European market for the Trodelvy-Keytruda combination.

The progress of the Trodelvy-Keytruda combination through the U.S. Food and Drug Administration (FDA) regulatory process is another critical factor. Gilead is expected to submit its application for accelerated approval in the first-line TNBC setting based on the EV-103/KEYNOTE-B87 study data, with an FDA decision potentially by Q1 2025. Any updates or accelerated review designations from the FDA could significantly impact the stock.

Initial sales figures and market uptake post-launch in Europe and potentially the U.S. will provide crucial insights into the therapy's commercial potential. Analysts will scrutinize Gilead's Q4 2024 and Q1 2025 earnings reports for early indications of revenue contribution from this expanded indication, particularly its ability to penetrate a competitive market. Key metrics will include prescription volumes and market share gains against existing therapies.

The evolving landscape of TNBC treatments, including ongoing clinical trials for novel therapies from competitors like AstraZeneca ($AZN) and Seagen ($SGEN), poses a long-term risk to market share. Any new data demonstrating superior efficacy or safety from rival compounds could impact Trodelvy's projected sales and competitive positioning, potentially reversing some of the current positive sentiment.